Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
Transplantation and Cellular Therapy ; 29(2 Supplement):S234-S235, 2023.
Article in English | EMBASE | ID: covidwho-2318630
2.
Respirology ; 28(Supplement 2):226, 2023.
Article in English | EMBASE | ID: covidwho-2312128
3.
Clinical and Experimental Rheumatology ; 41(2):466-467, 2023.
Article in English | EMBASE | ID: covidwho-2305732
4.
Medical Immunology (Russia) ; 25(1):155-166, 2023.
Article in Russian | EMBASE | ID: covidwho-2304429
6.
Allergy: European Journal of Allergy and Clinical Immunology ; 78(Supplement 111):323-324, 2023.
Article in English | EMBASE | ID: covidwho-2296144
7.
Allergy: European Journal of Allergy and Clinical Immunology ; 78(Supplement 111):301, 2023.
Article in English | EMBASE | ID: covidwho-2292379
9.
Russian Journal of Infection and Immunity ; 12(6):1051-1060, 2022.
Article in Russian | EMBASE | ID: covidwho-2263965
10.
Chinese Journal of Clinical Infectious Diseases ; 13(4):257-263, 2020.
Article in Chinese | EMBASE | ID: covidwho-2256102
11.
European Respiratory Journal Conference: European Respiratory Society International Congress, ERS ; 60(Supplement 66), 2022.
Article in English | EMBASE | ID: covidwho-2248890
12.
Paediatrics Eastern Europe ; 8(3):396-408, 2020.
Article in Russian | EMBASE | ID: covidwho-2281560
13.
Paediatrics Eastern Europe ; 8(3):396-408, 2020.
Article in Russian | EMBASE | ID: covidwho-2281559
14.
European Respiratory Journal Conference: European Respiratory Society International Congress, ERS ; 60(Supplement 66), 2022.
Article in English | EMBASE | ID: covidwho-2278659
16.
Thoracic and Cardiovascular Surgeon Conference: 52nd Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery, DGTHG Hamburg Germany ; 71(Supplement 1), 2023.
Article in English | EMBASE | ID: covidwho-2274697
17.
Neuroimmunology Reports ; 2 (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2273330
18.
Journal of Allergy and Clinical Immunology ; 151(2):AB211, 2023.
Article in English | EMBASE | ID: covidwho-2243855
19.
Russian Journal of Infection and Immunity ; 12(6):1051-1060, 2022.
Article in Russian | EMBASE | ID: covidwho-2241683
20.
Russian Journal of Infection and Immunity ; 12(6):1051-1060, 2022.
Article in Russian | EMBASE | ID: covidwho-2231253

ABSTRACT

Currently, as the SARS-CoV-2 pandemic evolves, there has been increasingly more attention paid to building natural and vaccine-induced immunity against SARS-CoV-2 and related disease known as COVID-19. Widespread preventive vaccination plays an important role in effectively protecting people from viral infections and can reduce national economic costs. Purpose - to study peripheral blood cell subset composition and magnitude of humoral response in vaccinated Gam-COVID-Vac subjects. The prospective study included 352 patients, of which 194 (119 women and 75 men) underwent an immunogram study and assessed level of anti-SARS-CoV-2 antibodies. In patients, the study of the lymphocyte subset composition and estimation of anti-SARS-CoV-2 antibodies was carried out at two time points - prior to vaccination and 90 days after inoculated component 1 of the Gam-COVID-Vac vaccine. In general, vaccination was well tolerated by patients, with no serious adverse events after immunization. The reaction to the vaccine (fever, malaise, headache, local reactions) was short-term (1-2 days) and more often noted after inoculated vaccine component 2. Comparatively analyzed immunogram parameters in females before and after vaccination revealed increased relative level of T-lymphocytes (CD3+), T-helper cell subset (CD3+CD4+), increased absolute and relative level of activated CD3+CD25+ T-lymphocytes, but decreased absolute and relative level of natural killer (CD3-CD56+CD16+) and natural killer T-cell (CD3+CD56+CD16+) cell subsets as well as decreased CD147 receptor expression on T-lymphocytes. Similar patterns were also found while examining the immunogram in males exepting increased level of lymphocytes and lowered CD147 expression on both T- and B-lymphocytes. No changes in the parameters of the immune T-cell arm was found. The high efficacy of the vaccine was confirmed by development of SARS-CoV-2-specific class G antiviral antibodies in 97.5% and 92.3% of vaccinated females and males, respectively. The data obtained evidence that: 1) vaccination induces a specific humoral immune response determined three months post-vaccination, and 2) it caused no serious disturbances in the immune system functioning, which could be reflected in the peripheral blood lymphocyte subset composition. Thus, the data presented allow to conclude that Gam-COVID-Vac is effective vaccine against SARS-CoV-2 infection. Copyright © 2022 Saint Petersburg Pasteur Institute. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL